Joint Clinical Trials Office

You are here

Randomized Phase II/III Study of Venetoclax (ABT-199) Plus Chemoimmunotherapy for MYC/BCL2 Double-hit and Double Expressing Lymphomas

Clinical Trial Details

If you decide to take part in this study, you will either get the usual chemotherapy (R-CHOP or dose adjusted EPOCH-R) for up to 18 weeks, or you will get the usual chemotherapy (R-CHOP or dose adjusted EPOCH-R) plus the study drug venetoclax for up to 18 weeks. The chemotherapy regimen known as R-CHOP includes the following drugs: rituximab (R), cyclophosphamide (C), doxorubicin (H), vincristine (O), and prednisone (P). The chemotherapy regimen known as dose adjusted EPOCH-R includes the following drugs: etoposide (E), prednisone (P), vincristine (O), cyclophosphamide (C), doxorubicin (H), and rituximab (R).

After you finish your study treatment, your doctor will continue to follow your condition and watch you for side effects for up to 5 years after you registered to the study. You will have clinic visits every 3 months for 2 years, then every 6 months until 5 years after you are registered to the study. After 5 years, your doctor will follow up with you either in clinic or by phone every 6 months for up to 10 years after you registered to the study.

Key Eligibility: 
  • Open to men and women 18 years of age and older who are diagnosed with DLBCL (Diffuse large B-cell lymphoma) or HGBCL (High grade B-cell lymphoma)
  • Participants must not have been previously treated for these conditions, and cannot be pregnant or nursing (if applicable)
  • Detailed eligibility will be reviewed when you contact the study team

Study contact by location

Upper East Side - Manhattan


Christine Tran, RN
(212) 746-6738

Primary Investigator(s)

Protocol ID(s)

Weill Cornell Medicine IRB #:






Open to Enrollment

Age Group